Aberrantly-expressed UCHL1 has been reported in breast, endometrial, ovarian and lung cancers, emerging as a potential drug target to suppress immune escape, tumor growth and metastasis [18,19,20,21,22,25]. Here, UCHL1 is linked to neoplasm.